Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
This article summarizes the literature on the various novel therapeutic options that have been investigated and are currently under development for the treatment of PSC.EXPERT OPINION: In the next decade, more than one drug will likely be approved for the treatment of the disease, and we will be looking at combination therapies for the optimal management of the disease.PMID:38480008 | DOI:10.1080/13543784.2024.2330738 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - March 13, 2024 Category: Drugs & Pharmacology Authors: Aalam Sohal Kris V Kowdley Source Type: research

Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
This article summarizes the literature on the various novel therapeutic options that have been investigated and are currently under development for the treatment of PSC.EXPERT OPINION-: In the next decade, more than one drug will likely be approved for the treatment of the disease, and we will be looking at combination therapies for the optimal management of the disease.PMID:38480008 | DOI:10.1080/13543784.2024.2330738 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - March 13, 2024 Category: Drugs & Pharmacology Authors: Aalam Sohal Kris V Kowdley Source Type: research

LESSONS LEARNED from EARLY-STAGE CLINICAL TRIALS for DIABETIC NEPHROPATHY
Expert Opin Investig Drugs. 2024 Mar 11. doi: 10.1080/13543784.2024.2326025. Online ahead of print.ABSTRACTINTRODUCTION: The evolution of treatment for diabetic nephropathy illustrates how basic biochemistry and physiology have led to new agents such as SGLT2 inhibitors and mineralocorticoid blockers. Conversely, clinical studies performed with these agents have suggested new concepts for investigational drug development. We reviewed currently available treatments for diabetic nephropathy and then analyzed early clinical trials of new agents to assess potential for future treatment modalities.AREAS COVERED: We searched Cli...
Source: Expert Opinion on Investigational Drugs - March 11, 2024 Category: Drugs & Pharmacology Authors: Marc Rendell Source Type: research

Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials
Expert Opin Investig Drugs. 2024 Mar 6:1-17. doi: 10.1080/13543784.2024.2326028. Online ahead of print.ABSTRACTINTRODUCTION: Antimicrobial resistance is a major threat to modern healthcare, and it is often regarded that the antibiotic pipeline is 'dry.'AREAS COVERED: Antimicrobial agents active against Gram negative bacilli in Phase I, II, or III clinical trials were reviewed.EXPERT OPINION: Nearly 50 antimicrobial agents (28 small molecules and 21 non-traditional antimicrobial agents) active against Gram-negative bacilli are currently in clinical trials. These have the potential to provide substantial improvements to the ...
Source: Expert Opinion on Investigational Drugs - March 6, 2024 Category: Drugs & Pharmacology Authors: David L Paterson Source Type: research